Stock Evaluator: STAAR Surgical Company (STAA)

STAAR Surgical Company STAA

$24.36 0.14 0.58%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,477,649
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Commentary & Analysis


Financial Summary

Share Statistics STAA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,203.4 $334.8 47%
Shares Out (Mil) 50.9 41.7 48%
Institutional Ownership 98.7% 77.3% 81%
Float (Mil) 24.5 34.7 32%
Beta 1.20 0.86 70%
Avg Daily Volume (000s) 1,206 266 74%
Price Change
(52-week)
30.1% 60.7% 69%
Growth STAA Industry
Median
Percentile
(All Stocks)
Sales (5yr) 7.9% 11.8% 50%
Net Income (5yr) (73.3%) (5.8%) 4%
EPS (5yr) (73.1%) 10.7% 1
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (24.0%) (16.1%) 27%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 7 7 7
Current EPS $0.221 $0.729 $0.989
Month Ago EPS $0.226 $0.736 $0.988
# Rev Up 2 1 0
# Rev Down 1 0 1
Three Months Ago EPS $0.197 $0.553 $0.770
Year/Year Chg 121.0% (144.9%) (166.4%)
Financials STAA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $290 $152 36%
Net Income (TTM) (Mil) ($21) ($11) 23%
EPS (TTM) ($0.423) ($0.500) 29%
Operating Cash Flow (TTM) (Mil) ($50) ($2) 9%
Net Cash Flow (TTM) (Mil) ($41) $1 21%
Long-Term Debt (Q1) (Mil) $31 $22 35%
Enterprise Value (Q1) (Mil) $1,467 $304 46%
Valuation STAA Industry
Median
Percentile
(All Stocks)
P/B 3.41 2.88 69%
P/E na 30.5 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.9 na
Ratios STAA Industry
Median
Percentile
(All Stocks)
Gross Margin 76.9% 59.1% 87%
Net Margin (7.2%) (7.7%) 23%
ROA (4.6%) (13.7%) 30%
ROE (6.0%) (15.9%) 30%
Liabilities to Assets 21.9% 44.9% 14%
F-Score 4 4 34%

STAAR Surgical Company did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors